160 related articles for article (PubMed ID: 32739465)
1. Leukotriene-Associated Rash in Aspirin-Exacerbated Respiratory Disease.
Laidlaw TM; Gakpo DH; Bensko JC; Buchheit K
J Allergy Clin Immunol Pract; 2020 Oct; 8(9):3170-3171. PubMed ID: 32739465
[No Abstract] [Full Text] [Related]
2. A retrospective analysis of bronchiectasis in patients with aspirin-exacerbated respiratory disease.
Chen YS; Bensko JC; Laidlaw TM; Buchheit KM
J Allergy Clin Immunol Pract; 2020 Sep; 8(8):2799-2801. PubMed ID: 32330669
[No Abstract] [Full Text] [Related]
3. COVID-19 in a series of patients with aspirin-exacerbated respiratory disease.
White AA; Cahill KN; Jerschow E; Kuruvilla M; Sehanobish E; Bensko J; Laidlaw TM; Levy JM
J Allergy Clin Immunol Pract; 2021 Jul; 9(7):2900-2903. PubMed ID: 33965591
[No Abstract] [Full Text] [Related]
4. Multidisciplinary single-center outcomes compared to two-center outcomes for the treatment of aspirin exacerbated respiratory disease.
Bosso JV; Tripathi SH; Kennedy DW; Kohanski MA; Cohen NA; Palmer JN; Adappa ND
J Allergy Clin Immunol Pract; 2021 Jun; 9(6):2498-2500. PubMed ID: 33548515
[No Abstract] [Full Text] [Related]
5. Aspirin-exacerbated respiratory disease: not always "adult-onset".
Tuttle KL; Schneider TR; Henrickson SE; Morris D; Abonia JP; Spergel JM; Laidlaw TM
J Allergy Clin Immunol Pract; 2016; 4(4):756-8. PubMed ID: 27393784
[No Abstract] [Full Text] [Related]
6. Aspirin-Exacerbated Respiratory Disease.
White AA; Stevenson DD
N Engl J Med; 2018 Sep; 379(11):1060-1070. PubMed ID: 30207919
[No Abstract] [Full Text] [Related]
7. If aspirin-exacerbated respiratory disease treatment is a jigsaw puzzle, where do the aspirin and biologic pieces go?
White AA
Ann Allergy Asthma Immunol; 2022 May; 128(5):484-485. PubMed ID: 35489798
[No Abstract] [Full Text] [Related]
8. Poor control of asthma symptoms with interleukin-5 inhibitors in four patients with aspirin-exacerbated respiratory disease.
Eid RC; Wudneh E; Zahid S; Cahill K; Jerschow E
Ann Allergy Asthma Immunol; 2020 Jan; 124(1):102-104. PubMed ID: 31605753
[No Abstract] [Full Text] [Related]
9. Aspirin desensitization achieved after omalizumab treatment in a patient with aspirin-exacerbated urticaria and respiratory disease.
Guillén D; Bobolea I; Calderon O; Fiandor A; Cabañas R ; Heredia R; Quirce S
J Investig Allergol Clin Immunol; 2015; 25(2):133-5. PubMed ID: 25997307
[No Abstract] [Full Text] [Related]
10. Utility of nasal mucus inflammatory profile as a biomarker of nasal polyp regrowth in aspirin-exacerbated respiratory disease.
Corey KB; Turner JH; Chowdhury NI; Chandra RK; Li P; Wu P; Cahill KN
J Allergy Clin Immunol Pract; 2022 Jun; 10(6):1644-1645.e1. PubMed ID: 35398556
[No Abstract] [Full Text] [Related]
11. Aspirin-exacerbated respiratory disease (AERD): Current understanding of AERD.
Taniguchi M; Mitsui C; Hayashi H; Ono E; Kajiwara K; Mita H; Watai K; Kamide Y; Fukutomi Y; Sekiya K; Higashi N
Allergol Int; 2019 Jul; 68(3):289-295. PubMed ID: 31235242
[TBL] [Abstract][Full Text] [Related]
12. Unique Effect of Aspirin Therapy on Biomarkers in Aspirin-exacerbated Respiratory Disease. A Prospective Trial.
Cahill KN; Cui J; Kothari P; Murphy K; Raby BA; Singer J; Israel E; Boyce JA; Laidlaw TM
Am J Respir Crit Care Med; 2019 Sep; 200(6):704-711. PubMed ID: 30978291
[No Abstract] [Full Text] [Related]
13. Omalizumab for Aspirin Hypersensitivity and Leukotriene Overproduction in Aspirin-exacerbated Respiratory Disease. A Randomized Controlled Trial.
Hayashi H; Fukutomi Y; Mitsui C; Kajiwara K; Watai K; Kamide Y; Nakamura Y; Hamada Y; Tomita Y; Sekiya K; Tsuburai T; Izuhara K; Wakahara K; Hashimoto N; Hasegawa Y; Taniguchi M
Am J Respir Crit Care Med; 2020 Jun; 201(12):1488-1498. PubMed ID: 32142372
[No Abstract] [Full Text] [Related]
14. Induced sputum eicosanoids during aspirin bronchial challenge of asthmatic patients with aspirin hypersensitivity.
Mastalerz L; Celejewska-Wójcik N; Wójcik K; Gielicz A; Januszek R; Cholewa A; Stręk P; Sanak M
Allergy; 2014 Nov; 69(11):1550-9. PubMed ID: 25123806
[TBL] [Abstract][Full Text] [Related]
15. Dupilumab increases aspirin tolerance in aspirin-exacerbated respiratory disease.
Mustafa SS; Vadamalai K
Ann Allergy Asthma Immunol; 2021 Jun; 126(6):738-739. PubMed ID: 33746062
[No Abstract] [Full Text] [Related]
16. Immunologic effects of aspirin desensitization and high-dose aspirin therapy in aspirin-exacerbated respiratory disease.
Cahill KN
J Allergy Clin Immunol; 2021 Aug; 148(2):344-347. PubMed ID: 34144108
[No Abstract] [Full Text] [Related]
17. Age as a factor in treatment of aspirin-exacerbated respiratory disease: relationship to required aspirin maintenance dose after desensitization.
Locke TB; Sweis AM; Gleeson PK; Lin TC; Civantos AM; Parhar HS; Corr AM; Kumar A; Salmon MK; Kohanski MA; Palmer JN; Bosso JV; Adappa ND
Int Forum Allergy Rhinol; 2020 Oct; 10(10):1180-1181. PubMed ID: 32761891
[No Abstract] [Full Text] [Related]
18. Increase in salivary cysteinyl-leukotriene concentration in patients with aspirin-intolerant asthma.
Ono E; Taniguchi M; Higashi N; Mita H; Yamaguchi H; Tatsuno S; Fukutomi Y; Tanimoto H; Sekiya K; Oshikata C; Tsuburai T; Tsurikisawa N; Otomo M; Maeda Y; Hasegawa M; Miyazaki E; Kumamoto T; Akiyama K
Allergol Int; 2011 Mar; 60(1):37-43. PubMed ID: 21099251
[TBL] [Abstract][Full Text] [Related]
19. Aspirin-Exacerbated Respiratory Disease.
Walgama ES; Hwang PH
Otolaryngol Clin North Am; 2017 Feb; 50(1):83-94. PubMed ID: 27888917
[TBL] [Abstract][Full Text] [Related]
20. Dupilumab as an adjunct to surgery in patients with aspirin-exacerbated respiratory disease.
Patel P; Bensko JC; Bhattacharyya N; Laidlaw TM; Buchheit KM
Ann Allergy Asthma Immunol; 2022 Mar; 128(3):326-328. PubMed ID: 34863953
[No Abstract] [Full Text] [Related]
[Next] [New Search]
